BrightSpring Health Services, I

Valuation Analysis

About the Company

BrightSpring Health Services, I en bref

BrightSpring Health Services, I (BTSG) is currently trading at 57,75 € with a market capitalization of 11,3 Md €. The trailing P/E ratio stands at 86.04x, with a forward P/E of 31.35x. The 52-week range spans from 16,57 € to 58,14 €; the current price is 0.7% below the yearly high. Year-over-year revenue growth stands at +25.6%. The net profit margin stands at 2.27%.

💰 Dividende

BrightSpring Health Services, I currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

16 analystes évaluent BrightSpring Health Services, I (BTSG) au consensus : Achat Fort. L'objectif de cours moyen est de 54,54 €, soit un potentiel de -5.57% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 42,72 € à 61,90 €.

BrightSpring Health Services, I : la thèse d'investissement en détail

BrightSpring Health Services, I (BTSG) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 25.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

Le scénario baissier

With a net margin of just 2.27%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. With a beta near 1.87, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 27.15x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 31.35x is meaningfully below the trailing 86.04x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (6.98%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy BrightSpring Health Services, I?

Compare top-rated brokers — low fees, trusted providers, fully regulated.